RS
SMMT icon

Rakuten Securities’s Summit Therapeutics SMMT Stock Holding History

Rakuten Securities’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Hold
5
– – ﹤0.01% 834
2025
Q4 		$87 Hold
5
– – ﹤0.01% 854
2025
Q3 		$103 Buy
+5
New +$121 ﹤0.01% 863
2025
Q1 		– Sell
-4,000
Closed -$71.4K – 857
2024
Q4 		$71.4K Buy
+4,000
New +$77.5K 0.03% 179

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rakuten Securities's SMMT Position: Q1 2026 in Review

Rakuten Securities held its Summit Therapeutics (SMMT) position steady in Q1 2026 at 5 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #834.

Rakuten Securities first reported a position in SMMT in Q4 2024 and has held it in 4 quarters since. The position peaked at $71.4K in Q4 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Rakuten Securities held 5 shares of Summit Therapeutics worth $95 as of Q1 2026.
  • Rakuten Securities left its Summit Therapeutics share count unchanged in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Rakuten Securities's portfolio in Q1 2026, its #834 holding.
  • Rakuten Securities first reported a position in Summit Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Rakuten Securities's Summit Therapeutics position peaked at $71.4K in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Rakuten Securities's 13F filing for Q1 2026, filed 1 May 2026.